Search clinical trials for: NSCLC, EGFR, Icotinib

Total 109 results

AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
Wu Nan

Not yet recruiting

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer | Bevacizumab | Tyrosine Kinase Inhibitor

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoIpower)

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.
The First Affiliated Hospital of Xiamen University

Recruiting

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Non-Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Recruiting

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (BELLA)

NSCLC

China
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (SMART)

Non Small Cell Lung Cancer | Brain Metastases

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Non-squamous Non-small Cell Lung Cancer

China
Nanfang Hospital of Southern Medical University

Not yet recruiting

Adjuvant Chemotherapy With or Without Intercalated Icotinib

Carcinoma, Non-Small-Cell Lung
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Beijing Haidian Hospital
307 Hospital of PLA; Peking University People's Hospital; 309th Hospital of Chinese...

Recruiting

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer(NSCLC)

China
Sun Yat-sen University

Recruiting

Icotinib for Completed Resected IB NSCLC With EGFR Mutation (CORIN)

Lung Neoplasms | Bronchial Neoplasms | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer

China
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Non-Small Cell Lung Cancer | EGFR Gene Mutation

China
Yuhong Li

Completed

Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Lady Davis Institute

Withdrawn

Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients (CH:II)

Metastatic NSCLC

Canada
Tonix Pharmaceuticals, Inc.

Completed

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RELIEF)

Fibromyalgia

United States
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (ICAPE)

Non-small Cell Lung Cancer

China
Li Peng
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (Icotinib)

Neurofibromatosis Type 2 | Vestibular Schwannoma

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (EVIDENCE)

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Terminated

Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Metastatic Breast Cancer

China
Array Biopharma, now a wholly owned subsidiary...

Withdrawn

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Non-Small Cell Lung Cancer

United States
Henan Cancer Hospital

Unknown

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Lung Adenocarcinoma

China
Fuda Cancer Hospital, Guangzhou

Completed

Cryotherapy Combine Icotinib for Advanced NSCLC Treatment

Lung Neoplasms
EMS

Completed

Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment

Musculoskeletal Pain

Brazil
Shanghai Chest Hospital

Completed

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Lung Adenocarcinoma | EGFR Activating Mutation
NorthShore University HealthSystem

Completed

Use of Cyclobenzaprine After Vaginal Surgery

Postoperative Pain

United States
Betta Pharmaceuticals Co., Ltd.

Completed

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Esophageal Carcinoma | Adenocarcinoma of the Gastroesophageal Junction

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (Convince)

NSCLC

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China

Completed

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Cancer
Takeda

Completed

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

Back Pain | Neck Pain | Spasm

Russian Federation
Novartis Pharmaceuticals

Completed

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Tumors Characterized by Genetic Abnormalities of ALK

Australia, Belgium, Germany, Netherlands, Spain, Italy, Singapore, Korea, Republic of, United Kingdom, United States, Canada
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-Small Cell Lung Cancer | Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd

Terminated

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Mild to Moderate Psoriasis

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
GlaxoSmithKline

Completed

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Metastatic Breast Cancer | Neoplasms, Breast

Japan
Sun Yat-sen University

Unknown

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation (ICTAN)

Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP)

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Sun Yat-sen University

Unknown

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Lung, Carcinoma

China

Search clinical trials for: NSCLC, EGFR, Icotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations